IPO - Tenaya Therapeutics, Inc.

Form Type: S-3

Filing Date: 2025-03-21

Corporate Action: Ipo

Type: New

Accession Number: 000119312525060227

Filing Summary: Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company incorporated in Delaware focusing on developing potentially curative therapies for heart disease. The company is advancing product candidates TN-201 and TN-401, which are gene therapies targeting specific genetic causes of heart disease. TN-201 is in clinical trials for hypertrophic cardiomyopathy (HCM) caused by MYBPC3 mutations, while TN-401 targets arrhythmogenic right ventricular cardiomyopathy (ARVC) linked to PKP2 gene mutations. The registration statement on Form S-3 has been filed to raise up to $300 million, detailing the offering of various securities including common and preferred stock, debt securities, and units. The registration allows the company to offer these securities on a delayed or continuous basis, enhancing its funding flexibility for ongoing clinical trials and operational needs. The document includes a base prospectus and a prospectus supplement specific to the sales agreement with Leerink Partners LLC, which mentions $69.8 million remaining under the sales agreement after the termination of a prior prospectus supplement. Tenaya Therapeutics emphasizes its focus on rigorous development and clinical testing of its product candidates, with various designations received from the FDA to accelerate their development.

Document Link: View Document